A Phase 1 interventional study of Prochlorperazine 0.5 mg IV over 5 sec and Inhaled prochlorperazine 0.625 mg in Migraine, sponsored by Nova Pneuma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Nova Pneuma Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 697 studies in Migraine Disorders with a site in United States — 92 open to participants now, 114 under way, 27 of them phase 3. Migraine Disorders · United States.
Among the 697 studies in Migraine Disorders with a site in United States, this one is the 365th largest by enrollment of the 610 interventional ones that give a count, is one of 15 that started in 2004, is one of 58 in phase 1, and was the 81st registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →92 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:
Salvia BioElectronics · Sites in United States
Ages 22–84
University of Colorado, Denver · Sites in United States
Ages 12–17
Columbia University · Sites in United States
Ages 18–55
TriGemX Bio, Inc. · Sites in United States
Ages 18–75
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
697 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 113 · Phase 3 151 · Phase 4 101
First in 1999; this study’s year is marked. 15 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 78 across the 610 interventional studies, 195 across the 84 observational. Of the 528 that completed or were terminated, 305 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
345 of 697 have an industry lead sponsor. The 10 most frequent:
Nova Pneuma Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Nova Pneuma Inc. has 1 study filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
47 of the studies in Migraine Disorders with a site in United States that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07645924Phase 3TriGemX Bio, Inc.A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | 2027-02 |
| NCT05598723Phase 3Naval Medical Center Camp LejeuneBOTOX® vs. XEOMIN® for Chronic Migraine | 2027-02-24 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
Add all 47 to your calendar (.ics) → With an account.
Among the 697 studies in Migraine Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of inhaled prochlorperazine
The objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of a single, inhaled dose of prochlorperazine (PCZ), administered as 1 or 2 puffs in healthy young volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prochlorperazine 0.5 mg IV over 5 sec crossover Inhaled prochlorperazine 0.625 mg
Drug: Prochlorperazine 0.5 mg IV over 5 sec · Drug: Inhaled prochlorperazine 0.625 mg · Drug: Prochlorperazine 10 mg IV over 5 sec
Inhaled Staccato prochlorperazine 1.25 mg
Drug: Inhaled prochlorperazine 1.25 mg
Inhaled Staccato prochlorperazine 2.5 mg
Drug: Inhaled prochlorperazine 2.5 mg
Inhaled Staccato prochlorperazine 5 mg
Drug: Inhaled prochlorperazine 5 mg
Inhaled Staccato prochlorperazine 10 mg
Drug: Inhaled prochlorperazine 10 mg
inhaled Staccato Placebo (0 mg)
Drug: Inhaled placebo
IV Prochlorperazine for bioavailability
Also known as: PCZ
Inhaled Staccato Prochlorperazine 0.625 mg
Also known as: PCZ
Inhaled Staccato Prochlorperazine 1.25 mg
Also known as: PCZ
Inhaled Staccato Prochlorperazine 2.5 mg
Also known as: PCZ
InhaledStaccato Prochlorperazine 5 mg
Also known as: PCZ
InhaledStaccato Prochlorperazine 10 mg
Also known as: PCZ
Inhaled Staccato Placebo (0 mg)
Also known as: ADASUVE placebo
Prochlorperazine 10 mg IV over 5 sec for patient qualification
Also known as: PCZ
Time to Peak (Tmax)
Time from dose to peak prochlorperazine concentration
Time frame: 24 hours
Absolute Bioavailability of Inhaled Prochlorperazine
Absolute bioavailability of inhaled prochlorperazine via AUC infinity
Time frame: 24 hours
Dose Proportionality of Inhaled Prochlorperazine by Power Analysis
Dose proportionality by power analysis examines the linear regression of the log-AUC versus log-Dose on a by-patient basis across all doses administered. The slope and 90% confidence interval (CI) provide a clear, quantitative (best practices) assessment of the relationship of drug delivered to dose administered. The units on such analyses are generally those of slope (rise over run), with 1.000 being "perfect". Although any positive slope might be considered clinically useful, a 90% CI within the criteria of 0.800-1.250 may be considered a delivery system which is "as good as it gets".
Time frame: 24 hours
| Milestone | Qualification & Crossover Arm, Inhaled Prochlorperazine vs IV | Inhaled Prochlorperazine 1.25 mg | Inhaled Prochlorperazine 2.5 mg | Inhaled Prochlorperazine 5 mg | Inhaled Prochlorperazine 10 mg | Inhaled Placebo |
|---|---|---|---|---|---|---|
| Started | 14 | 8 | 8 | 8 | 8 | 8 |
| Completed | 14 | 8 | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Time from dose to peak prochlorperazine concentration
| hours | 0.5 mg 5 Sec IV | 0.625 mg Inhaled Prochlorperazine | 1.25 mg Inhaled | 2.5 mg Inhaled | 5 mg Inhaled | 10 mg Inhaled |
|---|---|---|---|---|---|---|
| Time to Peak (Tmax) | 0.042 (0.025 to 0.067) | 0.033 (0.025 to 0.042) | 0.025 (0.013 to 0.082) | 0.033 (0.017 to 0.033) | 0.040 (0.017 to 0.115) | 0.033 (0.013 to 0.108) |
Absolute bioavailability of inhaled prochlorperazine via AUC infinity
| Fraction absorbed | Bioavailability Crossover Arm |
|---|---|
| Absolute Bioavailability of Inhaled Prochlorperazine | 0.98 (0.73 to 1.34) |
Dose proportionality by power analysis examines the linear regression of the log-AUC versus log-Dose on a by-patient basis across all doses administered. The slope and 90% confidence interval (CI) provide a clear, quantitative (best practices) assessment of the relationship of drug delivered to dose administered. The units on such analyses are generally those of slope (rise over run), with 1.000 being "perfect". Although any positive slope might be considered clinically useful, a 90% CI within the criteria of 0.800-1.250 may be considered a delivery system which is "as good as it gets".
| Slope of Power Regression | All Subjects Receiving Inhaled Prochloperazine |
|---|---|
| Dose Proportionality of Inhaled Prochlorperazine by Power Analysis | 1.089 (.99 to 1.2) |
Collected over Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IV Prochlorperazine 10 mg | 0/14 (0%) | 0/14 (0%) | 6/14 (42.9%) |
| IV Prochlorperazine 0.5 mg | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Inhaled Prochlorperazine 0.625 | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Inhaled Prochlorperazine 1.25 mg | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Inhaled Prochlorperazine 2.5 mg | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Inhaled Prochlorperazine 5 mg | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Inhaled Prochlorperazine 10 mg | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Inhaled Placebo | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Event | IV Prochlorperazine 10 mg | IV Prochlorperazine 0.5 mg | Inhaled Prochlorperazine 0.625 | Inhaled Prochlorperazine 1.25 mg | Inhaled Prochlorperazine 2.5 mg | Inhaled Prochlorperazine 5 mg | Inhaled Prochlorperazine 10 mg | Inhaled Placebo |
|---|---|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 0/14 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 2/8 | 0/8 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 0/14 | 0/8 | 0/8 | 2/8 | 1/8 | 0/8 | 1/8 | 0/8 |
| SomnolenceNervous system disorders | 3/14 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| Vision blurredEye disorders | 0/14 | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| Chest painGeneral disorders | 0/14 | 0/8 | 0/8 | 1/8 | 1/8 | 0/8 | 0/8 | 0/8 |
| Sensation of pressure in faceGeneral disorders | 0/14 | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| DysgeusiaNervous system disorders | 0/14 | 0/8 | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 |
| HeadacheNervous system disorders | 0/14 | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| AnxietyPsychiatric disorders | 1/14 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/8 |
| NauseaGastrointestinal disorders | 1/14 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 |
Safety Population
| Age, Categorical(Participants) | Qualification & Crossover, Inhaled Prochlorperazine vs IV | Inhaled Prochlorperazine 1.25 mg | Inhaled Prochlorperazine 2.5 mg | Inhaled Prochlorperazine 5 mg | Inhaled Prochlorperazine 10 mg | Inhaled Placebo | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 14 | 8 | 8 | 8 | 8 | 8 | 54 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Qualification & Crossover, Inhaled Prochlorperazine vs IV | Inhaled Prochlorperazine 1.25 mg | Inhaled Prochlorperazine 2.5 mg | Inhaled Prochlorperazine 5 mg | Inhaled Prochlorperazine 10 mg | Inhaled Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 29.4 ± 7.86 | 25.1 ± 3.44 | 25 ± 4.57 | 26.4 ± 8.94 | 28.8 ± 10.2 | 23.5 ± 7.03 | 25.8 ± 7.09 |
| Sex: Female, Male(Participants) | Qualification & Crossover, Inhaled Prochlorperazine vs IV | Inhaled Prochlorperazine 1.25 mg | Inhaled Prochlorperazine 2.5 mg | Inhaled Prochlorperazine 5 mg | Inhaled Prochlorperazine 10 mg | Inhaled Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 6 | 4 | 4 | 4 | 4 | 4 | 26 |
| Male | 8 | 4 | 4 | 4 | 4 | 4 | 28 |
| Region of Enrollment(participants) | Qualification & Crossover, Inhaled Prochlorperazine vs IV | Inhaled Prochlorperazine 1.25 mg | Inhaled Prochlorperazine 2.5 mg | Inhaled Prochlorperazine 5 mg | Inhaled Prochlorperazine 10 mg | Inhaled Placebo | Total |
|---|---|---|---|---|---|---|---|
| United States | 14 | 8 | 8 | 8 | 8 | 8 | 54 |
Plan to share: No — IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com
The record gives a start of Aug 2004, a primary completion of Oct 2004 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2018, 14 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prochlorperazine
Nova Pneuma Inc.